Bosentan in systemic sclerosis

Drugs of Today

Volumn 44, Issue 6, 2008, Pages 415-428

  Heresi, Gustavo A ^a   Minai, Omar A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; CYCLOSPORIN; ENDOTHELIN 1; GLIBENCLAMIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; KETOCONAZOLE; METHOTREXATE; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PROSTANOID; SILDENAFIL; SIMVASTATIN; TRANSFORMING GROWTH FACTOR BETA; WARFARIN;

ADVERSE OUTCOME; ANEMIA; ARTHRITIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIZZINESS; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG MECHANISM; DRUG MONITORING; DRUG POTENTIATION; DRUG WITHDRAWAL; FATIGUE; FEVER; FLUSHING; HEADACHE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERSTITIAL LUNG DISEASE; LEG EDEMA; LIVER FUNCTION TEST; MONOTHERAPY; MORBIDITY; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; PULMONARY HYPERTENSION; RASH; REVIEW; SIDE EFFECT; SURVIVAL RATE; SYSTEMIC SCLEROSIS; ULCER;

ANIMALS; ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION, PULMONARY; LUNG DISEASES, INTERSTITIAL; RECEPTORS, ENDOTHELIN; SCLERODERMA, SYSTEMIC; SKIN ULCER; SULFONAMIDES;

EID: 49149114916     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2008.44.6.1220138     Document Type: Review

References (71)

1. Ferri, C., Valentini, G., Cozzi, F. et al. Systemic sclerosis: Demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 2002, 81(2): 139-53.
2. Minai, O.A., Dweik, R.A., Arroliga, A.C. Manifestations of scleroderma pulmonary disease. Clin Chest Med 1998, 19(4): 713-31, viii-ix.
3. Avouac, J., Wipff, J., Kahan, A., Allanore, Y. Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: A meta-analysis of randomised controlled trials. Ann Rheum Dis 2008, 67(6): 808-14.
4. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980, 23(5): 581-90.
5. Mayes, M.D. Epidemiology of systemic sclerosis and related diseases. Curr Opin Rheumatol 1997, 9(6): 557-61.
6. Allcock, R.J., Forrest, I., Corris, P.A., Crook, P.R, Griffiths, I.D. A study of the prevalence of systemic sclerosis in northeast England. Rheumatology (Oxford) 2004, 43(5): 596-602.
7. Arnett, F.C., Howard, R.F., Tan, F. et al. Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma. Association with an Amerindian HLA haplotype. Arthritis Rheum 1996, 39(8): 1362-70.
8. Laing, T.J., Gillespie, B.W., Toth, M.B. et al. Racial differences in scleroderma among women in Michigan. Arthritis Rheum 1997, 40(4): 734-42.
9. LeRoy, E.C., Black, C., Fleischmajer, R. et al. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol 1988, 15(2): 202-5.
10. Minai, O.A., Budev, M.M. Diagnostic strategies for suspected pulmonary arterial hypertension: a primer for the internist. Cleve Clin J Med 2007, 74(10): 737-47.
11. Hachulla, E., Gressin, V., Guillevin, L. et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: A French nationwide prospective multicenter study. Arthritis Rheum 2005, 52(12): 3792-800.
12. Mukerjee, D., St. George, D., Coleiro, B. et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: Application of a registry approach. Ann Rheum Dis 2003, 62(11): 1088-93.
13. McGoon, M., Gutterman, D., Steen, V. et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004, 126(1, Suppl.): 14S-34S.
14. Yousem, S.A. The pulmonary pathologic manifestations of the CREST syndrome. Hum Pathol 1990, 21(5): 467-74.
15. Stupi, A.M., Steen, V.D., Owens, G.R., Barnes, E.L., Rodnan, G.P., Medsger, T.A. Jr. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 1986, 29(4): 515-24.
16. Scorza, R., Caronni, M., Bazzi, S. et al. Postmenopause is the main risk factor for developing isolated pulmonary hypertension in systemic sclerosis. Ann N Y Acad Sci 2002, 966: 238-46.
17. Steen, V.D., Ziegler, G.L., Rodnan, G.P., Medsger, T.A. Jr. Clinical and laboratory associations of anticentromere antibody in patients with progressive systemic sclerosis. Arthritis Rheum 1984, 27(2): 125-31.
18. Allanore, Y., Avouac, J., Wipff, J., Kahan, A. New therapeutic strategies in the management of systemic sclerosis. Expert Opin Pharmacother 2007, 8(5): 607-15.
19. Sacks, D.G., Okano, Y., Steen, V.D., Curtiss, E., Shapiro, L.S., Medsger, T.A. Jr. Isolated pulmonary hypertension in systemic sclerosis with diffuse cutaneous involvement: Association with serum anti-U3RNP antibody. J Rheumatol 1996, 23(4): 639-42.
20. Kawut, S.M., Taichman, D.B., Archer-Chicko, C.L., Palevsky, H.I., Kimmel, S.E. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003, 123(2): 344-50.
21. Tashkin, D.P., Elashoff, R., Clements, P.J. et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006, 354(25): 2655-66.
22. Steen, V.D., Conte, C., Owens, G.R., Medsger, T.A. Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994, 37(9): 1283-9.
23. Tashkin, D.P., Elashoff, R., Clements, P.J. et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007, 176(10): 1026-34.
24. Matucci-Cerinic, M., Steen, V.D., Furst, D.E., Seibold, J.R. Clinical trials in systemic sclerosis: Lessons learned and outcomes. Arthritis Res Ther 2007, 9(Suppl. 2): S7.
25. Riccardi, M.T., Chiala, A., Lannone, F., Grattagliano, V., Covelli, M., Lapadula, G. [Treatment of digital ulcers in systemtic sclerosis with endothelin-1 receptor antagonist (bosentan)]. Reumatismo 2007, 59(2): 135-9.
26. Abraham, D., Distler, O. How does endothelial cell injury start? The role of endothelin in systemic sclerosis. Arthritis Res Ther 2007, 9(Suppl. 2): S2.
27. Yamane, K., Miyauchi, T., Suzuki, N. et al. Significance of plasma endothelin-1 levels in patients with systemic sclerosis. J Rheumatol 1992, 19(10): 1566-71.
28. Vancheeswaran, R., Magoulas, T., Efrat, G. et al. Circulating endothelin-1 levels in systemic sclerosis subsets-A marker of fibrosis or vascular dysfunction? J Rheumatol 1994, 21(10): 1838-44.
29. Morelli, S., Ferri, C., Polettini, E. et al. Plasma endothelin-1 levels, pulmonary hypertension, and lung fibrosis in patients with systemic sclerosis. Am J Med 1995, 99(3): 255-60.
30. Abraham, D.J., Vancheeswaran, R., Dashwood, M.R. et al. Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol 1997, 151(3): 831-41.
31. Morelli, S., Ferri, C., Di Francesco, L. et al. Plasma endothelin-1 levels in patients with systemic sclerosis: Influence of pulmonary or systemic arterial hypertension. Ann Rheum Dis 1995, 54(9): 730-4.
32. Kuryliszyn-Moskal, A., Klimiuk, P.A., Sierakowski, S. Soluble adhesion molecules (sVCAM-1, sE-selectin), vascular endothelial growth factor (VEGF) and endothelin-1 in patients with systemic sclerosis: Relationship to organ systemic involvement. Clin Rheumatol 2005, 24(2): 111-6.
33. Becvar, R., Stork, J., Pesakova, V. et al. Clinical correlations of potential activity markers in systemic sclerosis. Ann N Y Acad Sci 2005, 1051: 404-12.
34. Kazzam, E., Waldenstrom, A., Hedner, T., Hedner, J., Caidahl, K. Endothelin may be pathogenic in systemic sclerosis of the heart. Int J Cardiol 1997, 60(1): 31-9.
35. Manetti, M., Neumann, E., Milia, A.F. et al. Severe fibrosis and increased expression of fibrogenic cytokines in the gastric wall of systemic sclerosis patients. Arthritis Rheum 2007, 56(10): 3442-7.
36. Kawaguchi, Y., Suzuki, K., Hara, M. et al. Increased endothelin-1 production in fibroblasts derived from patients with systemic sclerosis. Ann Rheum Dis 1994, 53(8): 506-10.
37. Odoux, C., Crestani, B., Lebrun, G. et al. Endothelin-1 secretion by alveolar macrophages in systemic sclerosis. Am J Respir Crit Care Med 1997, 156(5): 1429-35.
38. Cambrey, A.D., Harrison, N.K., Dawes, K.E. et al. Increased levels of endothelin-1 in bronchoalveolar lavage fluid from patients with systemic sclerosis contribute to fibroblast myogenic activity in vitro. Am J Respir Cell Mol Biol 1994, 11(4): 439-45.
39. Shi-Wen, X., Chen, Y., Denton, C.P. et al. Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell 2004, 15(6): 2707-19.
40. Shi-wen, X., Kennedy, L., Renzoni, E.A. et al. Endothelin is a downstream mediator of profibrotic responses to transforming growth factor beta in human lung fibroblasts. Arthritis Rheum 2007, 56(12): 4189-94.
41. Shi-Wen, X., Renzoni, E.A., Kennedy, L. et al. Endogenous endothelin-1 signaling contributes to type I collagen and CCN2 overexpression in fibrotic fibroblasts. Matrix Biol 2007, 26(8): 625-32.
42. Sfikakis, P.P., Papamichael, C., Stamatelopoulos, K.S. et al. Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis. Arthritis Rheum 2007, 56(6): 1985-93.
43. Iannone, F., Riccardi, M.T., Guiducci, S. et al. Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension. Ann Rheum Dis 2007, Epub ahead of print.
44. Clozel, M., Breu, V., Gray, G.A. et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 1994, 270(1): 228-35.
45. Langleben, D. Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Clin Chest Med 2007, 28(1): 117-25, viii.
46. Dingemanse, J., van Giersbergen, P.L. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet 2004, 43(15): 1089-115.
47. Rubin, L.J., Badesch, D.B., Barst, R.J. et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002, 346(12): 896-903.
48. Burgess, G., Hoogkamer, H., Collings, L., Dingemanse, J. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur J Clin Pharmacol 2008, 64(1): 43-50.
49. Minai, O.A., Budev, M.M. Treating pulmonary arterial hypertension: cautious hope in a deadly disease. Cleve Clin J Med 2007, 74(11): 789-93, 797-800, 802 passim.
50. Minai, O.A. The role of oral vasoactive agents in the treatment of pulmonary arterial hypertension. US Cardiovascular Disease. Touch Briefings 2006: 39-42.
51. Heresi, G.A., Minai, O.A. Lupus-associated pulmonary hypertension: Long-term response to vasoactive therapy. Respir Med 2007, 101(10): 2099-107.
52. Badesch, D.B., Tapson, V.F., McGoon, M.D. et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000, 132(6): 425-34.
53. Channick, R.N., Simonneau, G., Sitbon, O. et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebo-controlled study. Lancet 2001, 358(9288): 1119-23.
54. Galie, N., Hinderliter, A.L., Torbicki, A. et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol 2003, 41(8): 1380-6.
55. McLaughlin, V.V., Sitbon, O., Badesch, D.B. et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005, 25(2): 244-9.
56. Denton, C.P., Humbert, M., Rubin, L., Black, C.M. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: A subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 2006, 65(10): 1336-40.
57. Williams, M.H., Das, C., Handler, C.E. et al. Systemic sclerosis associated pulmonary hypertension: Improved survival in the current era. Heart 2006, 92(7): 926-32.
58. Denton, C.P., Pope, J.E., Peter, H.H. et al. Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Ann Rheum Dis 2007, Epub ahead of print.
59. Koh, E.T., Lee, P., Gladman, D.D., Abu-Shakra, M. Pulmonary hypertension in systemic sclerosis: An analysis of 17 patients. Br J Rheumatol 1996, 35(10): 989-93.
60. King, T.E. Jr., Behr, J., Brown, K.K. et al. BUILD-1: A randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008, 177(1): 75-81.
61. Buch, M.H., Denton, C.P., Furst, D.E. et al. Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: Reproducibility and correlations of the 6-min walk test. Ann Rheum Dis 2007, 66(2): 169-73.
62. Wells, A.U., Cullinan, P., Hansell, D.M. et al. Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 1994, 149(6): 1583-90.
63. Korn, J.H., Mayes, M., Matucci Cerinic, M. et al. Digital ulcers in systemic sclerosis: Prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004, 50(12): 3985-93.
64. Black, C., Furst, D.E. et al. Bosentan reduces the number of new digital ulcers in patients with systemic sclerosis - Open label extension to a double-blind trial. Ann Rheum Dis 2006, 65: S384.
65. Seibold, J.R., Denton, C.P. et al. Bosentan reduces the number of new digital ulcers in patients with systemic sclerosis. Ann Rheum Dis 2006, 65: S90.
66. Jain, M., Varga, J. Bosentan for the treatment of systemic sclerosis-associated pulmonary arterial hypertension, pulmonary fibrosis and digital ulcers. Expert Opin Pharmacother 2006, 7(11): 1487-501.
67. van Giersbergen, P.L., Halabi, A., Dingemanse, J. Pharmacokinetic interaction between bosentan and the oral contraceptives norethisterone and ethinyl estradiol. Int J Clin Pharmacol Ther 2006, 44(3): 113-8.
68. Channick, R.N., Sitbon, O., Barst, R.J., Manes, A., Rubin, L.J. Endothelin receptor antagonists in pulmonary arterial hypertension. J Am Coll Cardiol 2004, 43(12, Suppl. S): 62S-67S.
69. Humbert, M., Segal, E.S., Kiely, D.G., Carlsen, J., Schwierin, B., Hoeper, M.M. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J 2007, 30(2): 338-44.
70. Cozzi, F., Ostuni, P.A., Marotta, H., Sfriso, P., Favaro, M., Todesco, S. Bosentan may induce arthritis flare in patients with scleroderma concomitantly treated with methotrexate. Ann Rheum Dis 2006, 65(5): 692-3.
71. Nagai, Y., Yamanaka, M., Nishimura, S., Nakano, A., Hasegawa, A., Ishikawa, O. Drug eruption due to bosentan in a patient with systemic sclerosis. Mod Rheumatol 2006, 16(3): 188-90.